menu ☰
menu ˟

Pembrolizumab shows promise for high-risk, BCG-unresponsive nonmuscle-invasive bladder cancer

15 Feb 2019
SAN FRANCISCO — Pembrolizumab induced durable complete responses among patients with high-risk, nonmuscle-invasive, bacillus calmette-guérin-unresponsive bladder carcinoma in situ with or without papillary tumors, according to updated interim resu...

Click here to view the full article which appeared in Hematology Oncology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.